Health and Food
5 Pharma Stocks To Buy Along With Sanofi
Modern medicine is constantly progressing forward to help create a healthier world and respond to developing medical issues. In this quickly-changing industry, Sanofi (SNY) appears to be continuing on as a respectable company. Recent news stories show both good and bad signs for the company, but as a whole, I think it is still in a good position. I do not think the stock will be seeing significant changes as a result of these news events.
In the face of health-related crises, medical companies have a chance to meet a great need and make a great name for themselves. Sanofi is currently attempting to do this, as it has recently revealed a vaccine that could save millions from the mosquito-borne disease called dengue. The World Health Organization claims that up to 20,000 people around the world die from dengue each year. Sanofi believes this vaccine is “five years ahead of any known similar interventions.” Testing may confirm the effectiveness of the vaccine by September of this year, but this will begin to have positive effects on the company more immediately. If nothing else, it gives the company a good image and demonstrates its commitment to global health and progress.
Sanofi may be encountering some fierce competition from Novo Nordisk (NVO), but this will probably have a limited effect for the time being. Novo Nordisk has recently announced the results from the latest trial of its degludec, which is an insulin product that would compete with Sanofi’s Lantus.To continue reading, click here.